The activity of NF-jB/Rel transcription factors can downmodulate apoptosis in normal and neoplastic cells of the hematologic and other compartments, contributing in maintaining neoplastic clone survival and impairing response to therapy. Alterations in nfjb or ijB genes are documented in some hematologic neoplasias, while in others dysfunction in NF-jB/Rel-activating signaling pathways can be recognized. The prosurvival properties of NF-jB/Rel appear to rely on the induced expression of molecules (caspase inhibitors, Bcl2 protein family members, etc.), which interfere with the apoptosis pathway. Constitutive NF-jB/Rel activity in some hematologic malignancies could be advantageous for neoplastic clone expansion by counteracting stress stimuli (consumption of growth factors and metabolites) and immune system-triggered apoptosis; it is furthermore likely to play a central role in determining resistance to therapy. Based on this evidence, NFjB/Rel-blocking approaches have been introduced in antineoplastic strategies. The identification of NF-jB/Rel target genes relevant for survival in specific neoplasias is required in order to address tailored therapies and avoid possible detrimental effects due to widespread NF-jB/Rel inhibition. Moreover, comparative analyses of normal hematopoietic progenitors and neoplastic cell sensitivities to inhibitors of NF-jB/Rel and their target genes will allow to evaluate the impact of these tools on normal bone marrow. Regulation of apoptosis by NF-jB/Rel factors NF-kB/Rel transcription factors are dimers of proteins (p50/p105 or NF-kB1, p52/p100 or NF-kB2, p65 or RelA, c-Rel and RelB) containing an approximately 300 amino-acid REL homology domain (RHD), which mediates protein dimerization and binding to DNA.
Regulation of apoptosis by NF-jB/Rel factors NF-kB/Rel transcription factors are dimers of proteins (p50/p105 or NF-kB1, p52/p100 or NF-kB2, p65 or RelA, c-Rel and RelB) containing an approximately 300 amino-acid REL homology domain (RHD), which mediates protein dimerization and binding to DNA. 1 The RHD is also involved in interacting with the ankyrin repeats of IkB, a family of proteins coevolved with NF-kB/Rel. 1,2 NF-kB/Rel dimers are retained in the cytoplasm of several cell types by inhibitors of the IkB family. Growth factors, cytokines, hormones or other agents can induce, through the IKK (IkB-kinase) cascade or other kinases, 1,2 the phosphorylation and ubiquitin-mediated degradation of the IkB proteins, allowing the NF-kB/Rel dimers to reach the nucleus. 3 NF-kB/Rel activation is also induced by stress stimuli that provoke increases in the intracellular concentration of reactive oxygen species (ROS), imbalance in calcium ions fluxes and/or accumulation of unfolded proteins in the endoplasmic reticulum (RE). Such events trigger the activation of stress kinases and other modulators, which ultimately lead to IkB degradation. [1] [2] [3] A vast series of antineoplastic compounds can generate these stress signals, resulting in NF-kB/Rel activation. 4 Furthermore, NF-kB/Rel factors are constitutively found in the nuclei of normal primary B lymphocytes, thymocytes and neurons 1 and of some tumor cell types. 5 In cell nuclei, NF-kB/Rel dimers regulate the expression of a vast series of genes, which control inflammation, cell growth, differentiation or apoptosis. 1 The involvement of NF-kB/Rel factors in apoptosis modulation is proved by a large body of evidence. Indeed, the overexpression of p65-or c-Rel-containing dimers can impair apoptosis, while the inhibition of NF-kB/ Rel activity can enhance death induced by TNF-alpha, ionizing radiations or chemotherapeutic agents in many cell types. 1, [6] [7] [8] [9] [10] [11] Since proapoptotic stimuli, including TNFR ligands and stress signals, can result in the activation of an NF-kB/Rel-mediated, antiapoptotic pathway, cell survival appears to depend on the balance between these opposing inputs.
Owing to their prosurvival activity, NF-kB/Rel factors can contribute in both maintaining neoplastic clone survival and impairing response to therapy. [12] [13] [14] These findings have led to the development of antineoplastic strategies, pointing to inhibition of NF-kB/Rel activity and enhancement of spontaneous or therapy-induced death (Figure 1 ).
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Aberrant NF-kB/Rel activity in hematologic malignancies Aberrant activation of NF-kB/Rel factors contributes to lower the threshold of sensitivity to apoptosis in a vast range of hematologic malignancies. While alterations in nfkb or ikB genes are documented in some neoplasias, in other cases dysfunction in components of the NFkB/Rel-activating signaling pathways or influences of other mutated proteins on NF-kB/Rel can be recognized. 5 The first gene of the nfkb family to be found altered in human neoplasias was nfkb2, present on human chromosome 10q24. [16] [17] Gene rearrangements, including translocations and deletions, are found in many lymphomas and in a small percentage of chronic lymphocytic leukemias and multiple myelomas (MMs). [16] [17] [18] [19] The normal product of nfkb2 gene is first synthesized as a p100 precursor, whose COOH-terminus contains IkB-like ankyrin repeats and can display IkB-like inhibitor activity, blocking the nuclear translocation of NF-kB/ Rel dimers. Following proteolytic processing, the COOHterminus is degraded and p100 produces p52 protein. [20] [21] Dimers containing p52 can either weakly transactivate or even suppress the expression of target genes; p52 activity can result in apoptosis inhibition in some systems. 1 Recent evidence indicates that p100 carboxyl terminus displays, in addition to its IkB-like activity, a proapoptotic property, due to the presence of a death domain (DD) that can participate in caspase activation. 22 nfkb2 gene rearrangements that occur in human lymphoid tumors result in the generation of p100 mutants lacking the DD. Therefore, the loss of the proapoptotic properties of NF-kB2 protein can underlie its oncogenic activity. Furthermore, by disruption of its COOH-terminus, NF-kB2 can also simultaneously lose its IkB properties and generate the antiapoptotic protein p52, which might contribute to apoptosis suppression in neoplastic cells. [22] [23] Documented alterations in nfkb genes include amplification in c-rel.
24-27 c-rel represents the normal counterpart of a viral oncogene, v-rel, which causes aggressive leukemias/lymphomas in mice and transgenic animals. [28] [29] c-rel gene amplification (gains in 2p) is found either in non-Hodgkin's lymphoma, specifically in 420% of diffuse lymphomas with a large cell component (DLLC), and in classical Hodgkin lymphoma (cHL). [24] [25] [26] In cHL, c-rel gains appear to correlate with a nuclear localization of the protein, suggesting a constitutive activity of the transcription factor. 27 Genetic alterations also invest a member of the ikb family, bcl-3 gene, located on chromosome 19q13.1. The gene was cloned due to its location at a breakpoint junction in a rare t(14;19)(q32.3;q13.2) translocation in B-cell chronic lymphocytic leukemia. 30 Bcl-3 protein levels are high in such leukemias, as well as in some lymphomas, including a subgroup of anaplastic large lymphoma (ACLC) with t(2;5)(q23;q35), where a combination of genetic and epigenetic modifications is supposed to lead to bcl-3 overexpression. [31] [32] Bcl-3 protein shares with IkB family proteins the presence of ankyrin domains; however, at variance with the other IkB proteins, it is mainly nucleoplasmic and can enhance NFkB-dependent transcription (33) (34) (35) . Indeed, in the cell nucleus, Bcl-3 can either interact with suppressor p50 homodimers and remove them from DNA, or bind to p52 homodimers to coactivate transcription. [33] [34] [35] Furthermore, gene expression can be modulated by complex interactions of Bcl-3 with NFkB/Rel factors and other transcriptional regulators, such as histone acetylases. 36 Structural changes of nfkb1 (4q24) or relA (11q13) genes are only rarely found in leukemias, myelomas or lymphomas. 5 However, the activity of the gene products, which form the prototypical p50/p65 NFkB/Rel-transactivating dimer, is constitutive in a number of hematopoietic malignancies. Indeed, aberrations in the genomic asset of hematopoietic malignancies, although not affecting nfkb or ikb genes directly, can lead to the activation of NF-kB/Rel, as illustrated in the following examples.
Analysis of the chromosomal translocation t(1;14)(p22;q32) found in B-cell lymphomas of the mucosa-associated lymphoid tissue (MALT) led to the characterization of bcl10 gene, which is placed there under the control of the strong Ig transcriptional enhancers and therefore overexpressed. [37] [38] Wild-type Bcl10 protein contains a caspase recruitment domain (CARD) and, in normal B and T lymphocytes, connects antigen receptorinduced signals to the activation of NF-kB/Rel factors. [39] [40] The phosphorylation status of Bcl10 can apparently modulate cell apoptosis, possibly by regulating the binding of Bcl10 to its molecular partners in the NF-kB/Rel-activating machinery. 41 Bcl10 expression in MALT lymphoma correlates with NF-kB/Rel nuclear levels. 42 Another MALT lymphoma translocation, t(11;18)(q21;q21), produces API2-MALT1, by fusing the gene for the human caspase-like molecule MLT1 to the caspase inhibitor -encoding gene iap2;
43 such a fusion activates NF-kB/ Rel factors. 44 In a transfected cell system, Bcl10 and MLT1 proteins strongly interact and synergize in the activation of NFkB/Rel, 45 supporting a model in which the Bcl10-MALT1 complex activates the IKK cascade through a mechanism that is not yet elucidated. 40, 45 The Bcl10-MLT1 pathway is likely to exert an apoptosis-modulating role in MALT lymphomas, particularly in the Helicobacter pylori-negative gastric fraction of the disease, where t(11;18)(q21;q21) occurs at a high frequency. 46 High levels of constitutively active nuclear NF-kB/Rel factors are found in Hodgkin-Reed-Sternberg cells, [47] [48] [49] where their inhibition enhances cell apoptosis. 47, 49 NF-kB/Rel constitutive activity can result from unfunctional IkB proteins, 50 or, by a more recently identified and possibly more relevant mechanism, from ligand-independent activation of CD30 signaling, which drives TRAF protein aggregation and IKK-dependent activation of NF-kB/Rel. [51] [52] In acute lymphoblastic leukemias, constitutive NF-kB/Rel activation can be caused by the HTLV-1 Tax protein through its binding to the gamma component of the IKK complex, 53 or by the overexpression of MDM2, which can increase p65 promoter activity either directly or through the removal of p53. 54 In the myeloid compartment, p120BCR-ABL is reported to activate NF-kB/Rel, 55 while the promyelocytic leukemia protein PML can bind p65 and interfere with its activity. 56 These and other findings contribute to identification of mechanisms by which NF-kB/Rel is activated in neoplastic cells of the hematopoietic compartments. Other pieces of information deserve clarification. For example, although a constitutive nuclear activity of NF-kB/Rel factors is detectable in acute myeloid leukemia blasts, [57] [58] [59] [60] [61] [62] where impairs the apoptotic response to some chemotherapeutic compounds, 57, 59, 62 and an enhanced IKK activity is also found in acute myeloid blasts, 60 the alteration(s) on which this phenotypes rely are not yet recognized.
Regulatory role of NF-kB/Rel factors in the survival of neoplastic cells and normal progenitors A vast series of reports analyzed the effects of NF-kB/Rel inhibitors on cell survival in hematologic malignancies. 15 Furthermore, a number of laboratories attempted to verify the role of NF-kB/Rel in sustaining normal progenitor cell survival, particularly in order to evaluate a possible differential effect of NF-kB/Rel downmodulation on neoplastic vs normal cell apoptosis. [61] [62] 64, [70] [71] However, result interpretation is often complicated by the insufficient specificity of used inhibitors of NF-kB/Rel. Vectors, such as plasmids or adenoviruses, carrying NF-kB/Rel activity is induced by pro-apoptotic stimuli and downmodulates apoptosis. 66 On the other hand, proteasome inhibitors affect, in addition to IkB degradation, the stability of many proteins controlled by the ubiquitin-proteasome degradation pathway, 15, 67 and peptides that block the translocation of the nuclear localization signal (NLS)-containing proteins can act not only on NF-kB/Rel dimers but also on other NLS-containing factors. 15, 68 Even small inhibitors of IKK kinase complex subunits can interfere, although with different efficiencies, in the activities of different kinases. 69 In addition, findings observed by inhibiting NF-kB/Rel are not always compared to those obtained by hyperexpressing NF-kB/ Rel activity, which should be opposite and confirm the significance of the result.
NF-jB
As discussed in the previous section, in primary B chronic lymphocytic leukemia (B-CLL) and acute myeloblastic leukemia (AML) cells, constitutive nuclear levels of NF-kB/Rel activity were found. 57, [62] [63] Their specific downmodulation by decoy phosphorothioate oligonucleotides did not significantly affect basal cell survival, but instead enhanced the apoptotic response to chemotherapeutic compounds. 57, [62] [63] In Hodgkin's lymphoma cells, transfection with super-repressor IkBk-carrying constructs efficiently inhibited NF-kB/Rel activity and enhanced apoptosis induced by serum starvation or other stimuli, but barely affected cell survival in the absence of such proapoptotic inputs; 47 evidence of spontaneous, caspase 3-independent apoptosis was obtained by some authors, not in primary cells but in classical Hodgkin's disease (CHD) cell lines. 49 Normal hematopoietic progenitors were found not to display significant levels of NF-kB/Rel activation; [61] [62] 64 this was instead stimulated by some cytokines, 62,64,71 but NF-kB/Rel inhibition did not apparently affect the cytokine-mediated pro-survival activity, 64 which is known to involve, in addition to NF-kB/Rel activation, Akt kinase-mediated and other mechanisms. [72] [73] On the other hand, NF-kB/Rel activation could be induced in progenitors by chemotherapeutic compounds, such as etoposide, and NF-kB/ Rel-specific decoy oligonucleotides enhanced cell apoptosis in response to the drug. 62 Taken as a whole, these results indicate that NF-kB/Rel inhibition enhances the effect of pro-apoptotic stimuli in hematopologic malignancies and normal progenitors. As discussed in the following section, this effect can rely on the block of NF-kB/Rel-induced expression of molecules (caspase inhibitors, Bcl2 protein family members, etc.), which interfere with the apoptosis pathway initiated by chemotherapeutic compounds or other stress conditions. On the other hand, NF-kB/Rel activity constitutively found in primary cells of hematological malignancies slightly contributes to sustaining cell survival in the absence of pro-apoptotic stimuli. Constitutive NF-kB/Rel activity could be advantageous for neoplastic clone expansion by counteracting stress stimuli, due to the consumption of growth factors and metabolites, and apoptosis induced by cytotoxic cells of the immune system. Notably, it is likely to play a central role in contrasting the effect of proapoptotic, antineoplastic compounds and determining resistance to therapy.
Due to the enhancement of chemotherapy-induced apoptosis in normal hematopoietic progenitors by NF-kB/Rel inhibitors, the proposed use of NF-kB/Rel inhibitors as adjuvants in chemotherapy could imply a delay in bone marrow recovery. However, it cannot be ruled out that hematopoietic progenitors have a different threshold of sensitivity, compared to neoplastic cells, to specific NF-kB/Rel inhibitors in combination with drugs. This point deserves to be addressed by specific investigation.
Target genes and molecules of NF-kB/Rel in apoptosis regulation
NF-kB/Rel factors bind to kB sites located in the promoter regions of a vast series of genes.
1 Slightly different kB consensus sequences have been detected in the upstream regions of different genes and can be bound with diverse affinities by specific NF-kB/Rel dimers.
1 NF-kB/Rel activity can result in either stimulating or repressing gene expression, depending on the dimer subunit composition (a repressing activity has been attributed to p50/p50 homodimers, although it does not appear to be a general rule) and the context of promoter-binding factors. 1 Furthermore, interactions of NF-kB/Rel with widely acting o-activators, such as p300, can influence their availability for other transcription factors, like for example p53, therefore influencing other promoter assets indirectly. 74 Genes regulated by NF-kB/Rel have been identified by gene promoter analysis, mRNA differential display-based methods or expression profiling by cDNA microarray screening. 11, 66, [75] [76] These strategies are based on cell stimulation with an apoptosis inducer and NF-kB/Rel block by forced expression of superrepressor IkBk or siRNA introduction. A comparative analysis of mRNAs in cells with normal (NF-kB/Rel þ ) or downmodulated levels (NF-kB/Rel-) of NF-kB/Rel activity can lead to the detection of a certain number (depending on the cell type, proapoptotic stimulus and cDNA array used) of genes regulated by the transcription factors. It is then necessary to analyze whether the hyperexpression of single genes can substitute for NF-kB/Rel activity in NF-kB/Rel-cells: this can allow to verify the relevance of specific genes in the NF-kB/Rel-mediated pathway of apoptosis regulation. 11, 66, [75] [76] [77] Based on similar approaches, classes of apoptosis-modulating genes, whose expression is regulated by NF-kB/Rel, have been identified: some examples are reported in Table 1 . Table 1 NF-kB/Rel target genes in apoptosis modulation Among these genes, iaps (inhibitor of apoptosis protein) encode intracellular proteins that can bind and inhibit various caspases through their baculoviral IAP repeat (BIR) domains. 78 An X-linked iap (xiap) gene, survivin, is expressed in most cancers and leukemias and during fetal development, but not in the vast majority of normal adult cells, 79 with the exception of bone marrow CD34 þ cells. 80 In contrast to its expression predominantly during G2/M in neoplastic cells, 79 survivin is expressed throughout the cell cycle in normal CD34 þ hematopoietic progenitor cells stimulated by growth factors. [81] [82] Interestingly, xiap belongs to the class of genes whose mRNA is translated by a cap-independent mechanism, by ribosomal binding to internal ribosome entry sites (IRES) elements located in the 5 0 untraslated region. These genes can be translated in stress conditions and in cells primed to apoptosis, indicating that they are crucially involved in the regulation of survival and death processes. 83 Caspase regulators controlled by NF-kB/Rel also include flip, which encodes a protein with two death effector domains (DED), able to interfere with the DED-mediated interaction of procaspase 8 with FADD and block its activation. 84 NF-kB/Rel stimulates the expression of mdr1, whose product, P-glycoprotein (P-gp), is a membrane transporter belonging to the ATP-binding cassette (ABC) superfamily. 85 The protein is of relevance for cell apoptosis, since an increase in its levels can inhibit the activation of caspases 3 and 8, possibly through modulation of intracellular pH and/or interference with membrane events linked to signal transduction through death receptors. Furthermore, P-gp can modulate the efflux of antineoplastic compounds, therefore influencing cell uptake of the drugs and conferring resistance to therapy. 85 The involvement of mdr1 in the antiapoptotic effect of NF-kB/Rel has so far been demonstrated in nonhematological tumors, and has to be verified in leukemias and lymphomas.
Antiapoptotic genes regulated by NF-kB/Rel include, among others, bcl2 family members, 77, [86] [87] genes for enzymes, such as SOD-2, which control the redox state of the cell, 66, 88 and genes encoding proteins that can modulate NF-kB/Rel activation, by serving as transducer or regulatory proteins in the NF-kB/Rel-activating signaling machinery. 66, [89] [90] Furthermore, NF-kB/Rel activation results, either directly or indirectly, in repressing the expression of proapoptotic genes. Among these, there are forkhead and the endoplasmic reticulum stress-induced gene gadd153/chop, two genes for transcription factors, whose proapoptotic roles probably rely on their activities on more than one promoter. [91] [92] NF-kB/Rel activity also represses the expression of air (apoptosis-induced regulator), a proapoptotic gene whose expression is induced by stress conditions or Fas stimulation and whose function remains to be defined. 93 Interestingly, recent findings indicate that NF-kB/Rel can sustain cell survival through mechanisms different from the regulation of gene expression. 94 Such results came from studies in MM, a disease in which the antiapoptotic activity of NF-kB/ Rel, [95] [96] [97] [98] its modulation by antineoplastic compounds 99-100 and contribution to resistance to therapy [101] [102] have been deeply investigated. In MM.1S cells, p65 has been shown to bind human telomerase reverse transcriptase (hTERT) directly in the cytoplasm and mediate its translocation to nucleus. 94 Since hTERT nuclear activity is required for sustaining neoplastic cell proliferation, 103 its regulation by NF-kB/Rel could represent a pivotal mechanism in clone expansion. If verified in other cell contexts, this relevant information could constitute a major clue in the understanding of NF-kB/Rel biology and cell survival pathways.
Conclusions
Evidence of NF-kB/Rel-mediated inhibition of neoplastic cell apoptosis has induced the development of NF-kB/Rel-blocking strategies in therapy. Tools, such as proteasome, nuclear localization peptide or kinase inhibitors used for these attempts are often nonspecific and can lead to a vast series of undesired effects. A selective inhibition of NF-kB/Rel activity could, most probably, be attained by the design of small molecules, able to interfere with protein-protein binding of NF-kB/Rel to its regulators, cooperating transcription factors and other partners. 104 However, NF-kB/Rel factors act on a variety of genes, some of which can be devoid of any antiapoptotic role, while others can be relevant for apoptosis regulation only in specific neoplasias; the rest of the NF-kB/Rel-modulated genes, involved in specialized cell functions, can be responsible for considerable detrimental effects of NF-kB/Rel-targeting therapies. Our prospect is the planning of approaches, which interfere with the expression and/or activity of NF-kB/Rel single targets with relevant roles in specific neoplasias. Tailored studies in this direction are warranted.
